We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.68%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$38.1M
Cap. Flow
% of AUM
-17.06%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Mosaic Company
MOS
|
+$2.06M |
| 2 |
Petrobras
PBR
|
+$2M |
| 3 |
Vale
VALE
|
+$1.96M |
| 4 |
Cheniere Energy
CQP
|
+$1.94M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boise Cascade
BCC
|
+$2.62M |
| 2 |
Extra Space Storage
EXR
|
+$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
+$2.46M |
| 4 |
Imperial Oil
IMO
|
+$2.45M |
| 5 |
Avient
AVNT
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Syndax Pharmaceuticals
SNDX
$1.7B
| $152K | 0.07% |
8,723
-515
| -6% | -$8.67K |
|
227
Invesco Senior Loan ETF
BKLN
$6.96B
| $148K | 0.07% |
6,820
-2,863
| -30% | -$62.6K |
|
228
Cogent Biosciences
COGT
$6.76B
| $146K | 0.07% |
19,452
-1,158
| -6% | -$8.06K |
|
|
IGMS
229
DELISTED
IGM Biosciences
IGMS
| $146K | 0.07% |
5,469
-318
| -5% | -$5.92K |
|
230
Krystal Biotech
KRYS
$10.7B
| $146K | 0.07% |
2,199
-137
| -6% | -$8.55K |
|
|
MRUS
231
DELISTED
Merus
MRUS
| $146K | 0.07% |
5,513
-330
| -6% | -$8.84K |
|
232
Iovance Biotherapeutics
IOVA
$2.04B
| $144K | 0.06% |
8,663
-519
| -6% | -$8.03K |
|
|
MYOV
233
DELISTED
Myovant Sciences Ltd.
MYOV
| $142K | 0.06% |
10,655
-634
| -6% | -$8.5K |
|
234
Celldex Therapeutics
CLDX
$2.94B
| $141K | 0.06% |
4,131
-251
| -6% | -$8.02K |
|
|
MRNS
235
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $141K | 0.06% |
15,039
-893
| -6% | -$8.87K |
|
236
Atea Pharmaceuticals
AVIR
$370M
| $140K | 0.06% |
19,333
-1,148
| -6% | -$7.79K |
|
237
PMV Pharmaceuticals
PMVP
$57.1M
| $140K | 0.06% |
6,746
-405
| -6% | -$7.14K |
|
|
MORF
238
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $140K | 0.06% |
3,493
-200
| -5% | -$8.37K |
|
239
Crinetics Pharmaceuticals
CRNX
$8.88B
| $139K | 0.06% |
6,346
-380
| -6% | -$7.69K |
|
|
KYNB
240
Kyntra Bio
KYNB
$27.4M
| $139K | 0.06% |
462
-27
| -6% | -$9.41K |
|
241
Nkarta
NKTX
$152M
| $138K | 0.06% |
12,126
-717
| -6% | -$7.67K |
|
242
Seres Therapeutics
MCRB
$45M
| $137K | 0.06% |
962
-57
| -6% | -$8.77K |
|
243
Prothena Corp
PRTA
$448M
| $135K | 0.06% |
3,686
-215
| -6% | -$7.75K |
|
|
ITOS
244
DELISTED
iTeos Therapeutics
ITOS
| $134K | 0.06% |
4,161
-251
| -6% | -$9.12K |
|
|
NGM
245
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $134K | 0.06% |
8,782
-519
| -6% | -$8.1K |
|
|
BCYC
246
Bicycle Therapeutics
BCYC
$269M
| $131K | 0.06% |
2,987
-179
| -6% | -$8.36K |
|
247
CRISPR Therapeutics
CRSP
$4.69B
| $131K | 0.06% |
2,081
-122
| -6% | -$7.66K |
|
248
Gossamer Bio
GOSS
$101M
| $131K | 0.06% |
15,039
-893
| -6% | -$8.61K |
|
|
AMRS
249
DELISTED
Amyris Inc.
AMRS
| $130K | 0.06% |
29,766
-1,761
| -6% | -$7.9K |
|
|
SWTX
250
DELISTED
SpringWorks Therapeutics
SWTX
| $129K | 0.06% |
2,288
-137
| -6% | -$7.84K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, Virtus ETF Advisers held 420 positions worth $223M, down 16% from $265M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers withdrew a net $38.1M in Q1 2022, closing 47 positions and reducing 231 holdings. Its most notable exit was Boise Cascade, an estimated $2.62M position sold in full.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 14% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Virtus ETF Advisers opened a new position in The Mosaic Company worth $2.75M.
- Virtus ETF Advisers's largest Q1 2022 buy was The Mosaic Company: 41,283 shares worth $2.75M.
- Virtus ETF Advisers added most to Agnico Eagle Mines in Q1 2022, an estimated $1.28M increase.
- Virtus ETF Advisers's biggest Q1 2022 reduction was Gold Fields, cutting an estimated $1.09M.
- Virtus ETF Advisers fully exited Boise Cascade in Q1 2022, selling an estimated $2.62M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $223M portfolio in Q1 2022.
- Virtus ETF Advisers opened 44 new positions and closed 47 in Q1 2022.
- Virtus ETF Advisers's portfolio value fell 16% quarter-over-quarter to $223M.
Based on Virtus ETF Advisers's 13F filing for Q1 2022, filed 16 May 2022.